Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of MK-1293 vs Lantus in type 1 diabetes
2011-003971-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin glargine in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in A1C at Week 24. Started Jan 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2011-003971-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003971-12.